{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:33:24Z","timestamp":1790775204469,"version":"4.1.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors are widely used in clinical practice, necessitating appropriate management of immune-related adverse events (irAEs). Although severe neurologic irAEs are less common, they often lead to poor outcomes, requiring early detection and prompt intervention. An 88-year-old woman with invasive urothelial carcinoma received six cycles of gemcitabine plus carboplatin followed by avelumab, an anti-programmed cell death ligand 1 antibody, as maintenance therapy. One week later, she developed progressive limb weakness and was diagnosed with irAE myositis based on elevated creatine kinase (CK) levels and imaging findings. Early treatment with methylprednisolone pulse therapy, followed by prednisolone [1\u00a0mg\/kg body weight (BW)], led to rapid improvement, and no relapse occurred after prednisolone completion at 4 months. IrAE myositis has clinical, pathological, and immunological features that differ from those of known inflammatory muscle diseases. In this case, the time to onset and the presence of antistriational antibodies were consistent with previous reports focusing on anti-programmed cell death 1 antibodies, whereas ocular symptoms, myocarditis, and myasthenia gravis, which are considered characteristic of irAE myositis, were not observed. Given the expected increase in high-grade neurological irAEs, accumulating case reports is essential to better understand the differences in clinical presentation and prognosis, which may vary depending on drug-specific effects and autoantibody profiles. Furthermore, this case suggests that some patients with irAE myositis may successfully taper or discontinue prednisolone earlier than traditionally expected.<\/jats:p>","DOI":"10.1093\/mrcr\/rxaf025","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T07:46:52Z","timestamp":1748591212000},"source":"Crossref","is-referenced-by-count":3,"title":["A case of irAE myositis with positive antistriational antibodies after anti-PD-L1 antibody administration: A case report"],"prefix":"10.1093","volume":"9","author":[{"given":"Hironori","family":"Ando","sequence":"first","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]},{"name":"Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8820-7556","authenticated-orcid":false,"given":"Ken","family":"Takao","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]},{"name":"Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makie","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]},{"name":"Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]},{"name":"Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]},{"name":"Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute , Kobe ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokuyuki","family":"Hirose","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]},{"name":"Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]},{"name":"Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]},{"name":"Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Hirota","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]},{"name":"Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Horikawa","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]},{"name":"Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yabe","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]},{"name":"Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine , Gifu ,","place":["Japan"]},{"name":"Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute , Kobe ,","place":["Japan"]},{"name":"Center for One Medicine Innovative Translational Research, Gifu University Institute of Advanced Studies , Gifu ,","place":["Japan"]},{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"2025080201012118700_ref1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Manuel","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025080201012118700_ref2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Michael","year":"2018","journal-title":"N Engl J Med"},{"key":"2025080201012118700_ref3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11912-019-0859-2","article-title":"Neurologic immune-related adverse events associated with immune checkpoint inhibition","volume":"21","author":"Peter","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"2025080201012118700_ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025080201012118700_ref5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","article-title":"Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors","volume":"18","author":"Justin","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2025080201012118700_ref6","doi-asserted-by":"crossref","first-page":"1227049","DOI":"10.3389\/fnins.2023.1227049","article-title":"Neurological adverse events associated with PD-1\/PD-L1 immune checkpoint inhibitors","volume":"17","author":"Zhou","year":"2023","journal-title":"Front Neurosci"},{"key":"2025080201012118700_ref7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaut.2019.03.005","article-title":"Inflammatory myopathy associated with PD-1 inhibitors","volume":"100","author":"Seki","year":"2019","journal-title":"J Autoimmun"},{"key":"2025080201012118700_ref8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Alvaro","year":"2019","journal-title":"Eur J Cancer"},{"key":"2025080201012118700_ref9","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2025080201012118700_ref10","article-title":"Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern","volume":"19","author":"Garcia","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2025080201012118700_ref11","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"2025080201012118700_ref12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025080201012118700_ref13","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s13311-022-01184-0","article-title":"Paraneoplastic autoimmune neurological syndromes and the role of immune checkpoint inhibitors","volume":"19","author":"Duong","year":"2022","journal-title":"Neurotherapeutics"},{"key":"2025080201012118700_ref14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12883-019-1416-1","article-title":"Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report","volume":"19","author":"Kamo","year":"2019","journal-title":"BMC Neurol"},{"key":"2025080201012118700_ref15","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1038\/s41598-019-41730-z","article-title":"Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and\/or myocarditis","volume":"9","author":"Kufukihara","year":"2019","journal-title":"Sci Rep"},{"key":"2025080201012118700_ref16","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdw126","article-title":"Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma","volume":"27","author":"Vallet","year":"2016","journal-title":"Ann Oncol"},{"key":"2025080201012118700_ref17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2019-000028","article-title":"Myasthenia gravis and concurrent myositis following PD-L1 checkpoint inhibitor for non-small cell lung cancer","volume":"2","author":"Phua","year":"2020","journal-title":"BMJ Neurol Open"},{"key":"2025080201012118700_ref18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/intimm\/dxq049","article-title":"PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1","volume":"22","author":"Ghiotto","year":"2010","journal-title":"Int Immunol"},{"key":"2025080201012118700_ref19","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2217\/fon-2020-1222","article-title":"Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials","volume":"17","author":"Sonpavde","year":"2021","journal-title":"Future Oncol"},{"key":"2025080201012118700_ref20","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/archneurol.2009.229","article-title":"Autoimmune targets of heart and skeletal muscles in myasthenia gravis","volume":"66","author":"Suzuki","year":"2009","journal-title":"Arch Neurol"},{"key":"2025080201012118700_ref21","first-page":"442","article-title":"Striational antibodies in myasthenia gravis: reactivity and possible clinical significance","volume":"62","author":"Romi","year":"2005","journal-title":"Auch Neurol"},{"key":"2025080201012118700_ref22","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.3390\/ijms21093054","article-title":"Immune checkpoint inhibitor-related myositis: from biology to bedside","volume":"21","author":"Solimando","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025080201012118700_ref23","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025080201012118700_ref24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of Immunotherapy-Related Toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"2025080201012118700_ref25","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamaneurol.2017.0934","article-title":"Skeletal muscle involvement in antisynthetase syndrome","volume":"74","author":"Noguchi","year":"2017","journal-title":"JAMA Neurol"},{"key":"2025080201012118700_ref26","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/annonc\/mdw655","article-title":"Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm","volume":"28","author":"Haddox","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxaf025\/63406926\/rxaf025.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf025\/63406926\/rxaf025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf025\/63406926\/rxaf025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T05:01:40Z","timestamp":1754110900000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxaf025\/8153901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxaf025","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"rxaf025"}}